P53 autoantibodies in 1006 patients followed up for breast cancer

Breast Cancer Res. 2000;2(6):438-43. doi: 10.1186/bcr91. Epub 2000 Aug 21.

Abstract

Serial plasma samples from 1006 patients with breast cancer revealed: (i) no correlation of p53 autoantibody status with disease status at the time of sample collection, or with menopausal status at time of primary diagnosis of breast cancer; (ii) 155 out of 1006 (15%) of patients were positive for p53 autoantibodies, and these patients tended to have a persistent autoantibody status throughout follow up, irrespective of disease behaviour; and (iii) where a negative autoantibody status was found at primary diagnosis of breast cancer, this negative status persisted throughout follow up, irrespective of later disease behaviour. We conclude that screening for p53 autoantibody status is not informative on residual tumour activity nor on therapeutic responsiveness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Autoantibodies / blood*
  • Autoantigens / immunology*
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Cohort Studies
  • Disease Progression
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Follow-Up Studies
  • Humans
  • Mastectomy
  • Menopause
  • Middle Aged
  • Neoplasm Proteins / immunology*
  • Tamoxifen / administration & dosage
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / immunology*

Substances

  • Autoantibodies
  • Autoantigens
  • Neoplasm Proteins
  • Tumor Suppressor Protein p53
  • Tamoxifen